Chairman, Scientific Advisory Board
Joaquim Trias is an expert on inflammation and infectious disease and currently serves as Anthera Pharmaceutical’s Senior Vice President, Preclinical Development. Anthera is a privately held biopharmaceutical company developing anti-inflammatory drugs. Dr. Trias is also the President and CEO of Virex Pharmaceuticals, Inc. Prior to founding Virex, Dr. Trias was Vice President of Drug Discovery Research at Vicuron for 8 years where he directed the internal discovery projects‚ from concept to clinical candidate‚ and participated in the clinical development programs at Vicuron. These efforts led to the discovery of novel antibiotics that entered clinical trials. Prior to Vicuron‚ Dr. Trias worked at Microcide Pharmaceuticals for three years where he initiated various discovery programs in infectious diseases. In all Dr. Trias has 15 years of VC backed pharmaceutical experience and has co-founded three companies which have raised more than $50M in in venture financing. Prior to entering the pharmaceutical industry‚ Dr. Trias held different academic positions namely‚ Associate Professor at the Faculty of Pharmacy of the University of Barcelona and Research Fellow at the School of Medicine Pitie–Salpetriere of the University of Paris VI. Dr. Trias holds 15 patents and is the author of over 40 peer reviewed publications or patents. He obtained his Ph.D. at the University of Barcelona and completed his training at the University of California at Berkeley.
Dr. Chin is an Internist with extensive expertise in drug development. He has overseen over 40 Investigational New Drug (IND) Applications for new molecular entities and new indications, as well as eight New Drug Applications (NDAs)/Biologic License Applications (BLAs), and has authored a major textbook on clinical trial medicine. Dr. Chin was CEO of the Institute for OneWorld Health, a nonprofit dedicated to advancing the development of medicines for treatment of infectious diseases affecting the developing world. Previously, he was President and CEO of OXiGENE, and earlier served as SVP and Head of Global Development for Elan Corporation, where he had worldwide responsibility for Clinical Development, Regulatory, Biostatistics, CMC, QA/Compliance, Safety and Medical Affairs. Dr. Chin has also held various clinical and scientific roles for Genentech, Inc. including Head of Clinical Research for the Biotherapeutics Unit, overseeing approximately half of the drugs at Genentech, and began his career at Procter and Gamble Pharmaceuticals, where he served as Associate Medical Director. He previously served on the Adjunct Clinical Faculty of Stanford University School of Medicine and currently serves on the Boards of Directors of RXi Pharmaceuticals, a company founded by Craig Mello developing novel RNAi based treatments for human diseases. He received a B.A. in Biology, magna cum laude, from Harvard University and the equivalent of a J.D. with honors from Oxford University in England under a Rhodes scholarship. Dr. Chin holds a Medical Degree from Harvard Medical School and is licensed to practice medicine in California.
Dr. Kaliner is a practising physician and is Past-President of the American Academy of Asthma, Allergy and Immunology (the largest society of allergists in the world). He is Past-President of the World Allergy Organizations. He was the Director of the Allergic Diseases Section of the NIH’s National Institute of Allergic and Infectious Diseases and has published over 450 articles, manuscripts, supplements and books, with a focus on asthma, allergy, anaphylaxis and sinusitis. He has been the chairman of the American Board of Allergy and Immunology (the organization which certifies allergists as to their training) and has overseen training programs in which more than 100 fellows in allergic disease were trained. The University of Maryland Medical School recognized him with the Honor Award and Gold Key as their outstanding Alumnus (1994).
Dr. Blessing-Moore is a practising allergist and recognized authority in the treatment of allergic conditions and asthma. She is board certified in pediatric allergy and pediatric pulmonology. Dr. Blessing-Moore serves on the Practice Parameters Task Force for the Joint Council of the Academy of Asthma, Allergy and Immunology and the American College of Asthma, Allergy and Immunology. She was formerly head of the allergy fellowship program at Stanford Medical School and served as a member of the FDA advisory panel for Respiratory-Allergy drugs.
Dr. Goldsobel is a practising allergist, a Clinical Professor at the University of California San Francisco and an Adjunct Associate Professor at Stanford University Medical Center where he teaches students, residents and fellows. He is a past president of the California Society of Allergy, Asthma & Immunology and has been selected to “Best Doctors in America” from 2001 to 2008. He graduated Phi Beta Kappa from University of Texas at Austin and attended medical school at the University of Texas. He completed his residency at UCSF and his Allergy/Immunology fellowship at UCLA.
Dr. Bleske is Associate Professor of Pharmacy at the University of Michigan College of Pharmacy and Clinical Pharmacist for the Cardiology Service, University of Michigan Hospital in Ann Arbor. Dr. Bleske’s research has focused in the area of heart failure, cardiopulmonary resuscitation, nitric oxide, and pharmacotherapy including natural products. He has authored over 100 published abstracts, articles and book chapters. He is a graduate of Wayne State University and the University of Minnesota College of Pharmacy. Dr. Bleske is a Fellow of the American College of Pharmacy.